ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Abatacept

Also written as “Belatacept”, “abatacept” and “Abatacept (BMS-188667)”.

Its studies are mostly in Arthritis, Rheumatoid · Arthritis, Juvenile · Psoriasis · Arthritis, Psoriatic · Lupus Nephritis, led by 3 companies.

Drug pageAbatacept: every studyAll 218 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Dec 19, 201268 company-led studies, 2 open or runningNext primary completion: Dec 30, 2032 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only652 open or runningphase 4since Dec 19, 2012May 3, 2002Dec 30, 2032phase 3 · NCT04877288
Simcere Pharmaceutical Groupits history only20 open or runningphase 3since Mar 10, 2016Mar 10, 2016none ahead
Amneal Pharmaceuticals10 open or runningphase 1since Jan 31, 2025Jan 31, 2025none ahead

Also a collaborator on its studies: Ono Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Amneal Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 31, 2025First study: phase 1 study in Arthritis, RheumatoidFirst studyNCT06929039 · 300 enrolled · Canada

TargetBeta

CD80 →CD86 →read by rule
“T-lymphocyte activation antigen CD86 inhibitor; T-lymphocyte activation antigen CD80 inhibitor”ChEMBL 37, by rule

Studies

The one study Amneal Pharmaceuticals leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06929039Arthritis, Rheumatoid · Canada1CompletedOct 16, 2024300

How it is read

Names in the registry

  • “Abatacept”, 53 entries
  • “Belatacept”, 9 entries
  • “abatacept”, 4 entries
  • “Abatacept (BMS-188667)”, 4 entries
  • “belatacept”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.